# Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

> **NCT05468320** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 51 (actual)

## Conditions studied

- Thrombotic Thrombocytopenic Purpura

## Interventions

- **DRUG:** Caplacizumab
- **DRUG:** Corticosteroids
- **BIOLOGICAL:** anti-CD20 antibody

## Key facts

- **NCT ID:** NCT05468320
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-21
- **Primary completion:** 2024-12-26
- **Final completion:** 2024-12-26
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468320, "Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05468320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*